PA
KERX

Perceptive Advisors’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Perceptive Advisors’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-200,000
Closed -$2.83M – 190
2014
Q4 		$2.83M Hold
200,000
– – 0.24% 76
2014
Q3 		$2.75M Buy
+200,000
New +$3.06M 0.28% 60

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
ACM
Abrams Capital Management Boston, Massachusetts $4.64B AUM 1.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CLM
ClearBridge LLC (Maryland) Baltimore, Maryland $329M AUM 9.73% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
RHJA
Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Perceptive Advisors's KERX Position: Q1 2018 in Review

Perceptive Advisors sold out of Keryx Biopharmaceuticals Inc (KERX) in Q1 2018, closing a stake of 83,386 shares — an estimated $388K sold.

Perceptive Advisors first reported a position in KERX in Q2 2013 and held it in 7 quarters. The position peaked at $4.69M in Q1 2014. 125 funds tracked by Wall St. Rank hold KERX as of Q1 2018.

  • Perceptive Advisors reported no remaining Keryx Biopharmaceuticals Inc position as of Q1 2018 after selling out during the quarter.
  • Perceptive Advisors sold 83,386 Keryx Biopharmaceuticals Inc shares in Q1 2018, an estimated $388K.
  • Perceptive Advisors first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 7 quarters.
  • Perceptive Advisors's Keryx Biopharmaceuticals Inc position peaked at $4.69M in Q1 2014.
  • 125 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q1 2018.

Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.